Barclays
COLL icon

Barclays’s Collegium Pharmaceutical COLL Stock Holding History

Barclays’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-45,000
Closed -$701K – 6777
2016
Q4 		$701K Hold
45,000
– – ﹤0.01% 3083
2016
Q3 		$867K Buy
+45,000
New +$534K ﹤0.01% 2756

Other funds holding COLL

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Peregrine Capital Management
Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Barclays's COLL Position: Q3 2026 in Review

Barclays reduced its Collegium Pharmaceutical (COLL) stake by 66% in Q3 2026, selling an estimated $2.06M and leaving 36,987 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

Barclays first reported a position in COLL in Q2 2015 and has held it in 46 quarters since. The position peaked at $4.8M in Q4 2025. 118 funds tracked by Wall St. Rank hold COLL as of Q3 2026.

  • Barclays held 36,987 shares of Collegium Pharmaceutical worth $807K as of Q3 2026.
  • Barclays sold 70,683 Collegium Pharmaceutical shares in Q3 2026, an estimated $2.06M.
  • Collegium Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3194 holding.
  • Barclays first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 46 quarters since.
  • Barclays's Collegium Pharmaceutical position peaked at $4.8M in Q4 2025.
  • 118 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.